Physicians

Veltuzumab

Background

Veltuzumab is a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes currently under development for the treatment of non-Hodgkin’s lymphoma (NHL) and autoimmune diseases.

The Phase I/II trials of Veltuzumab, in the subcutaneous formulation, for the treatment of ITP and chronic lymphocytic leukemia (CLL) are now completed. In addition, a Phase I/II clinical trial, funded by a grant from the National Institutes of Health, is investigating the combination of Veltuzumab with yttrium-90-labeled Epratuzumab in patients with aggressive NHL.

Clinical Studies

Immune Thrombocytopenic Purpura (ITP)

Updated results from the Phase I/II trial in adult patients with chronic ITP who failed at least one standard therapy were presented at the 16th Congress of the European Hematology Association in 2011. For more information on this clinical trial, please go to clinicaltrials.gov.

Non-Hodgkin’s Lymphoma/Chronic Lymphocytic Leukemia(NHL/CLL)

Results from the study in patients with NHL have been published in Haematologica. Information on the Phase I/II trial in patients with CLL can be obtained from clinicaltrials.gov.

Aggressive Non-Hodgkin’s Lymphoma

The Phase I/II study combines Veltuzumab with yttrium-90-labeled Epratuzumab in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma clinicaltrials.gov.

References

  • Subcutaneous injections of low-dose anti-CD20 Veltuzumab for patients with relapsed immune thrombocytopenia (ITP). A. Liebman, N. Saleh, J. Bussel, P. Bernstein, G. Negrea, C. Onyegbula, M. Farber, M. Bernhold, A. Horne, K. Teoh, A. Wegener, D. Goldenberg.  Haematologica 96(s2):abstract 0527, 2011.

  • Subcutaneous injections of low-dose Veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin lymphoma. O.G. Negrea, R. Elstrom, S.L. Allen, K.R. Rai, R.M. Abbasi, C.M. Farber, N. Teoh, H. Horne, W.A. Wegener, D.M. Goldenberg. Haematologica 96:567-573, 2010.

  • Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. D.M. Goldenberg, F. Morschhauser, W.A. Wegener. Leuk Lymphoma 51:747-755, 2010.

  • Properties and structure-function relationships of Veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. D.M. Goldenberg, E.A. Rossi, R. Stein, T.M. Cardillo, M.S. Czuczman, F.J. Hernandez-Ilizaliturri, H.J. Hansen, C. Chang. Blood 113:1062-1070, 2009.

  • Humanized anti-CD20 antibody, Veltuzumab, in refractory or recurrent non-Hodgkin's lymphoma: Phase I/II results. F. Morschhauser, J.P. Leonard, L. Fayad, B. Coiffier, M. Petillon, M. Coleman, S.J. Schuster, M.J.S. Dyer, H. Horne, N. Teoh, W.A. Wegener, D.M. Goldenberg. J Clin Oncol 27:3346-3353, 2009.




Immunomedics - Physicians